Aquestive Therapeutics (NASDAQ:AQST) Insider Lori Braender Sells 40,102 Shares

Aquestive Therapeutics, Inc. (NASDAQ:AQST) insider Lori Braender sold 40,102 shares of the company’s stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $4.17, for a total transaction of $167,225.34. Following the completion of the transaction, the insider directly owned 442,879 shares of the company’s stock, valued at $1,846,805.43. This represents a 8.30% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Aquestive Therapeutics Stock Down 1.3%

NASDAQ:AQST traded down $0.06 on Thursday, reaching $4.21. 178,631 shares of the company’s stock traded hands, compared to its average volume of 5,513,083. The stock has a 50-day simple moving average of $4.08 and a 200-day simple moving average of $5.21. The firm has a market cap of $514.28 million, a PE ratio of -5.42 and a beta of 1.61. Aquestive Therapeutics, Inc. has a 12 month low of $2.12 and a 12 month high of $7.55.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings data on Wednesday, March 4th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.13). The firm had revenue of $13.02 million during the quarter, compared to analyst estimates of $13.28 million. On average, equities analysts anticipate that Aquestive Therapeutics, Inc. will post -0.46 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Lake Street Capital set a $6.00 price target on Aquestive Therapeutics in a research note on Tuesday, February 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aquestive Therapeutics in a research report on Wednesday, January 21st. Finally, Wall Street Zen raised shares of Aquestive Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, March 7th. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $8.80.

Institutional Investors Weigh In On Aquestive Therapeutics

Several large investors have recently made changes to their positions in AQST. NewEdge Advisors LLC purchased a new stake in shares of Aquestive Therapeutics in the third quarter worth about $28,000. BNP Paribas Financial Markets grew its holdings in Aquestive Therapeutics by 78.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company’s stock valued at $31,000 after buying an additional 4,134 shares in the last quarter. Modern Wealth Management LLC purchased a new position in Aquestive Therapeutics during the 2nd quarter valued at approximately $33,000. Cox Capital Mgt LLC bought a new stake in Aquestive Therapeutics in the 3rd quarter worth approximately $59,000. Finally, Kestra Private Wealth Services LLC bought a new stake in Aquestive Therapeutics in the 3rd quarter worth approximately $60,000. 32.45% of the stock is owned by institutional investors.

Aquestive Therapeutics News Roundup

Here are the key news stories impacting Aquestive Therapeutics this week:

• Positive Sentiment: HC Wainwright raised several near‑term EPS estimates and lifted its FY2026 view (less negative) — modest analytical support for the story and potential relief if guidance/progress continues. HC Wainwright Estimates
• Positive Sentiment: Independent coverage remains constructive on Anaphylm: a Seeking Alpha piece reiterates a Buy and argues the CRL issues are addressable (packaging/labeling), forecasting a high approval/adoption probability if the planned PK study succeeds. That supports upside tied to regulatory progress. Seeking Alpha: Anaphylm
• Neutral Sentiment: Short‑interest data in feeds is currently reporting anomalous/zero values (likely data error) and should not be relied on for a short‑squeeze narrative until official reporting clears up. (No reliable link.)
• Negative Sentiment: Multiple law firms and notice filings indicate a securities class action has been filed and several firms are soliciting lead‑plaintiff roles for purchasers from June 16, 2025 to Jan 8, 2026 — this increases legal exposure, potential costs, and investor uncertainty. Representative notices: Bernstein Liebhard, Rosen, Portnoy/others. Bernstein Liebhard Alert Portnoy Notice
• Negative Sentiment: A PRNewswire item highlights a lawsuit alleging an analyst (Cantor) slashed AQST’s price target from $15 to $8 (Jan 9), linking that cut to a >37% one‑day loss for certain holders — adds a contested narrative about analyst conduct and market impact. PR Newswire: Analyst Lawsuit
• Negative Sentiment: Large insider sales were disclosed on March 10 (CEO and multiple senior officers sold sizeable blocks at ~ $4.17), reducing insider ownership materially — often interpreted by markets as a negative signal about near‑term prospects or liquidity needs. Representative SEC filing (CEO): SEC Filing (CEO Sale)

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.